Clinical trial
Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast…
NCT00002826 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00002826 |
|---|---|
| Title | Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer |
| Official title | A PILOT PHASE II TRIAL OF PSC 833 MODULATION OF MULTIDRUG RESISTANCE TO PACLITAXEL IN THE TREATMENT OF METASTATIC CARCINOMA OF THE BREAST |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | paclitaxel, valspodar |
| Enrollment | 36 |
| Start date | Aug 14, 1997 |
| Primary completion | Nov 1, 2003 |
| First posted | May 12, 2004 |
| Last update posted | Jun 7, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: